Search Results

Displaying Results 3851-3875 of 26730 "'D'"

Jul 31, 2026, 07:47 ET AbbVie Reports Second-Quarter 2026 Financial Results

revenues.On a GAAP basis, research and development (R&D) expense was 13.8 percent of net revenues. The adjusted R&D expense was 13.6 percent of net revenues.Acquired IPR&D and milestones expense was 1.7 percent of net revenues.

More news about: AbbVie


Jul 31, 2026, 07:30 ET Ballard Reports Q2 2026 Results

the year; our objective of being profitable by the end of 2027; corporate development activities; and impacts of investments in manufacturing and R&D capabilities and cost reduction initiatives.These forward-looking statements reflect Ballard's current expectations as contemplated under section

More news about: Ballard Power Systems Inc.


Jul 31, 2026, 07:30 ET Ballard Reports Q2 2026 Results

the year; our objective of being profitable by the end of 2027; corporate development activities; and impacts of investments in manufacturing and R&D capabilities and cost reduction initiatives.These forward-looking statements reflect Ballard's current expectations as contemplated under section

More news about: Ballard Power Systems Inc.


Jul 31, 2026, 07:00 ET Enbridge Reports Strong Second Quarter Results, Reaffirms 2026 Guidance and Grows Secured Backlog to $41B

Connector), expanding existing U.S. Gulf Coast footprint and increasing connectivity between Tres Palacios and Freeport LNG Sanctioned the 2.6 Bcf/d Bay Runner Twin Pipeline (Bay Runner Twin), providing Permian natural gas supply to the Rio Grande LNG facility under long-term take-or-pay agreements Completed

More news about: Enbridge Inc.


Jul 31, 2026, 06:30 ET TXNM Energy Reports Second Quarter 2026 Results

237Merger related costs2d

More news about: TXNM Energy, Inc.


Jul 31, 2026, 06:16 ET e&, 2026년 상반기 연결 매출 381억 디르함 달성하며 11.6% 증가

multimedia:https://www.prnewswire.com/kr/news-releases/u0065u0026u002Du0032u0030u0032u0036uB144u002DuC0C1uBC18uAE30u002DuC5F0uACB0u002DuB9E4uCD9Cu002Du0033u0038u0031uC5B5u002DuB514uB974uD568u002D-302839961.htmlSOURCE

More news about: e&


Jul 31, 2026, 06:03 ET ECARX-Backed Chip Maker SiEngine Secures US$200M Equity Financing to Accelerate Vertical Silicon-to-Software SDV Innovation

strong cost-performance advantages for intelligent mobility platforms.This US$200 million equity injection will fuel SiEngine's next-phase R&D, production capacity expansion, globalization and international customer growth, further strengthening the unique ECARX vertical silicon-to-software

More news about: ECARX Holdings Inc.


Jul 31, 2026, 05:31 ET JSBC Launches "Chinese Wisdom" Book Series to Deepen Cross-Civilizational Dialogue Through Print

medium of print.The first book draws from a documentary of the same name, part of JSBC's "Incredible Encounter" series. Using cutting-edge AIGC, 3D reconstruction, and large language models, the documentary brought Confucius and Socrates — two giants of humanity's Axial Age — back to life for an imagined

More news about: InJiangsu


Jul 31, 2026, 05:30 ET Autohome Inc. to Announce Second Quarter and Interim 2026 Financial Results on August 20, 2026

https://register-conf.media-server.com/register/BI296b7d951b7846ef99ed79972fbe1931Please use the conference access information to join the call ten minutes before the call is scheduled

More news about: Autohome Inc.


Jul 31, 2026, 05:19 ET 232 Aerospace Engineering Students of Chandigarh University complete industry training at ISRO, DRDO, HAL & other Aerospace Organisations

""CU's Aerospace Engineering program offers students hands-on exposure through advanced infrastructure, including a Cessna 172D Aircraft, MiG-21 Aircraft Engine, Subsonic Wind Tunnel, High-Speed Jet Facility and Aircraft Simulator. Our 'Centre for Advanced Simulation', using ANSYS

More news about: Chandigarh University


Jul 31, 2026, 04:13 ET 우클라 마닐라 연구 결과: 통신사 VoLTE 네트워크, 음성 품질 및 안정성에서 OTT 앱 능가

multimedia:https://www.prnewswire.com/kr/news-releases/uC6B0uD074uB77Cu002DuB9C8uB2D0uB77Cu002DuC5F0uAD6Cu002DuACB0uACFCu003Au002DuD1B5uC2E0uC0ACu002Du0076u006Fu006Cu0074u0065u002DuB124uD2B8uC6CC-302839871.htmlSOURCE

More news about: Ookla


Jul 31, 2026, 04:03 ET IMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand

integrated R&D platform that enables innovation across both small molecules and emerging modalities, including ADCs and degraders. Additionally, we have forged partnerships with leading global biotech and China pharmaceutical companies to date, as validation of our pipeline and R&D platform.About

More news about: IMPACT Therapeutics


Jul 31, 2026, 03:48 ET IMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand

integrated R&D platform that enables innovation across both small molecules and emerging modalities, including ADCs and degraders. Additionally, we have forged partnerships with leading global biotech and China pharmaceutical companies to date, as validation of our pipeline and R&D platform.About

More news about: IMPACT Therapeutics


Jul 31, 2026, 03:39 ET 컨티뉴이티 바이오사이언시스, 신임 이사회 멤버에 비키 파푸치스

multimedia:https://www.prnewswire.com/kr/news-releases/uCEE8uD2F0uB274uC774uD2F0u002DuBC14uC774uC624uC0ACuC774uC5B8uC2DCuC2A4u002Cu002DuC2E0uC784u002DuC774uC0ACuD68Cu002DuBA64uBC84uC5D0u002DuBE44-302839842.htmlSOURCE

More news about: Continuity Biosciences LLC


Jul 31, 2026, 02:15 ET CellOrigin Unveils Two Novel Solid-Tumor Cell Therapy Candidates at ASCO 2026, Partners with Walvax for In Vivo CAR Clinical Trial

industrial capabilities, the two companies aim to accelerate the clinical translation of novel therapies for solid tumors.Through sustained R&D investment, CellOrigin has established a comprehensive in vivo CAR technology platform addressing solid tumors, autoimmune diseases and organ fibrosis.

More news about: CellOrigin


Jul 31, 2026, 02:04 ET FIRST AMGEN SCHOLARS PROGRAM IN INDIA LAUNCHES AT IIIT HYDERABAD

ecosystem.""We are delighted to serve as the host institution for the first Amgen Scholars Program in India," said Deva Priyakumar, Professor & Dean (R&D), IIIT Hyderabad. "The program aligns well with our research-led approach to education and provides undergraduate students with an exceptional opportunity

More news about: Amgen


Jul 31, 2026, 00:56 ET 아부다비 문화관광부, 2026년 12월 11일 구겐하임 아부다비 개관 발표

multimedia:https://www.prnewswire.com/kr/news-releases/uC544uBD80uB2E4uBE44u002DuBB38uD654uAD00uAD11uBD80u002Cu002Du0032u0030u0032u0036uB144u002Du0031u0032uC6D4u002Du0031u0031uC77Cu002DuAD6CuAC90-302839723.htmlSOURCE

More news about: Department of Culture and Tourism - Abu Dhabi


Jul 31, 2026, 00:10 ET ALIMENTATION COUCHE-TARD ANNOUNCES AGREEMENT TO ACQUIRE CONTROLLING STAKE IN ŻABKA GROUP AND LAUNCHES VOLUNTARY TENDER OFFER

5 Calculated as pre IFRS-16 earnings before interest and tax divided by enterprise value, plus cumulative capex, D&A excluding right-of-use, and working capital. Assumes acquisition of 100% of Żabka Group equity.Transaction

More news about: Alimentation Couche-Tard inc.


Jul 30, 2026, 22:31 ET XCMG, 인도네시아서 첫 해외 신에너지 공장 생산 개시

전환을 가속하고 있으며, 글로벌 사업 운영과 친환경 산업 발전을 양대 핵심 전략 우선순위로 삼고 있다. XCMG의 첫 해외 신에너지 공장 가동은 이 두 우선순위를 통합한 전략적 행보다.이 기지는 완성 장비 제조, 현지 작업 환경에 맞춘 현지화 연구개발(R&D), 현지 서비스를 결합해 제품 인도 기간을 단축하고 인도네시아의 광업, 인프라 및 산업단지 물류 분야 전반의 수요에 대응하게 된다.또한 현지 스마트 제조 역량을 기반으로 전기 건설기계를 대규모로 공급, 인도네시아 주요 산업의 저탄소 전환도 지원한다.

More news about: XCMG Machinery


Jul 30, 2026, 21:55 ET MSFT Deadline: MSFT Investors Have Opportunity to Lead Microsoft Corporation Securities Fraud Lawsuit

in order to improve the competitive positioning of its critical Copilot family of products and increase its AI-related research and development ("R&D"); and (4) as a result, Microsoft had failed to convert a significant percentage of its commercial Microsoft 365 users to paid Copilot subscriptions

More news about: THE ROSEN LAW FIRM, P. A.


Jul 30, 2026, 21:01 ET Kaigene Enters into Exclusive Licensing Agreement with Taisho Pharmaceutical for Next-Generation Autoimmune Asset KG006 in Japan

antibody Nanozora®. Taisho continues to expand its biopharmaceutical footprint through strategic pipelines, licensing opportunities, and ongoing R&D investments. To learn more, please visit www.taisho.co.jp.Media Contact:

More news about: Kaigene


Jul 30, 2026, 18:18 ET Labor & Employment Attorneys, at Blumenthal Nordrehaug Bhowmik De Blouw LLP, File Suit Against CRST Expedited, Inc., for Alleged Failure to Pay Accurate Wages

meal and rest periods, (d) failed to provide accurate itemized wage statements, (e) failed to reimburse for required expenses, (f) failed to pay sick wages, and (g) failed to provide

More news about: Blumenthal Nordrehaug Bhowmik De Blouw LLP


Jul 30, 2026, 16:35 ET Summit Midstream Corporation Schedules Second Quarter 2026 Earnings Call

Call (https://register-conf.media-server.com/register/BI8cebf785fce846a9bb80ae80660d3cbc).

More news about: Summit Midstream Corporation


Jul 30, 2026, 16:30 ET Corteva Delivers Strong 1H 2026, Raises FY 2026 Outlook, On-Track for October 1 Separation

quarter of 2025. Price/mix, reductions in net royalty expense, and ongoing cost and productivity actions more than offset lower volumes and increased R&D and functional cost.  Segment operating EBITDA margin improved by over 230 basis points versus the prior-year period.

More news about: Corteva Agriscience


Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.